{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=esomeprazole+40+mg",
    "query": {
      "intervention": "esomeprazole 40 mg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 49,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=esomeprazole+40+mg&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-21T08:42:10.259Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01844583",
      "title": "Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Alisertib",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2013-06-25",
      "completion_date": "2016-09-06",
      "has_results": true,
      "last_update_posted_date": "2019-03-25",
      "last_synced_at": "2026-09-21T08:42:10.259Z",
      "location_count": 7,
      "location_summary": "Sarasota, Florida • St Louis, Missouri • Oklahoma City, Oklahoma + 4 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01844583"
    },
    {
      "nct_id": "NCT01079884",
      "title": "Gastroesophageal Reflux Disease (GERD)/Nighttime Heartburn and Driving Performance",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "GERD"
      ],
      "interventions": [
        {
          "name": "esomeprazole 40 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David A. Johnson, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 18,
      "start_date": "2008-07",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2012-02-22",
      "last_synced_at": "2026-09-21T08:42:10.259Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01079884"
    },
    {
      "nct_id": "NCT00206245",
      "title": "A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "GERD With Erosive Esophagitis"
      ],
      "interventions": [
        {
          "name": "AZD0865",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 1400,
      "start_date": "2004-05",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2013-01-04",
      "last_synced_at": "2026-09-21T08:42:10.259Z",
      "location_count": 77,
      "location_summary": "Alabaster, Alabama • Huntsville, Alabama • Tucson, Arizona + 74 more",
      "locations": [
        {
          "city": "Alabaster",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00206245"
    },
    {
      "nct_id": "NCT00658528",
      "title": "Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastroesophageal Reflux Disease (GERD)"
      ],
      "interventions": [
        {
          "name": "Rabeprazole sodium",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1061,
      "start_date": "2008-02",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2015-12-21",
      "last_synced_at": "2026-09-21T08:42:10.259Z",
      "location_count": 1,
      "location_summary": "Anaheim, California",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00658528"
    },
    {
      "nct_id": "NCT00441727",
      "title": "Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastric Ulcer",
        "Duodenal Ulcer"
      ],
      "interventions": [
        {
          "name": "Esomeprazole 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole 20 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2426,
      "start_date": "2007-02",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2012-07-16",
      "last_synced_at": "2026-09-21T08:42:10.259Z",
      "location_count": 55,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 52 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00441727"
    },
    {
      "nct_id": "NCT00978016",
      "title": "A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastroesophageal Reflux Disease"
      ],
      "interventions": [
        {
          "name": "arbaclofen placarbil-Cohort 1",
          "type": "DRUG"
        },
        {
          "name": "Placebo-Cohort 5",
          "type": "DRUG"
        },
        {
          "name": "arbaclofen placarbil-Cohort 2",
          "type": "DRUG"
        },
        {
          "name": "arbaclofen placarbil-Cohort 3",
          "type": "DRUG"
        },
        {
          "name": "arbaclofen placarbil-Cohort 4",
          "type": "DRUG"
        },
        {
          "name": "PPI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "XenoPort, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 460,
      "start_date": "2009-09",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-09-21T08:42:10.259Z",
      "location_count": 62,
      "location_summary": "Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00978016"
    },
    {
      "nct_id": "NCT00241514",
      "title": "Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "GERD"
      ],
      "interventions": [
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 334,
      "start_date": "2001-02",
      "completion_date": "2003-02",
      "has_results": false,
      "last_update_posted_date": "2011-01-21",
      "last_synced_at": "2026-09-21T08:42:10.259Z",
      "location_count": 19,
      "location_summary": "Tucson, Arizona • Anaheim, California • Orange, California + 16 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00241514"
    },
    {
      "nct_id": "NCT01147588",
      "title": "Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "lansoprazole",
          "type": "DRUG"
        },
        {
          "name": "omeprazole",
          "type": "DRUG"
        },
        {
          "name": "esomeprazole",
          "type": "DRUG"
        },
        {
          "name": "clopidogrel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 149,
      "start_date": "2010-05",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2011-06-28",
      "last_synced_at": "2026-09-21T08:42:10.259Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01147588"
    },
    {
      "nct_id": "NCT00474903",
      "title": "Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Barrett Esophagus",
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "acetylsalicylic acid",
          "type": "DRUG"
        },
        {
          "name": "esomeprazole magnesium",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2007-04",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2014-07-02",
      "last_synced_at": "2026-09-21T08:42:10.259Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00474903"
    },
    {
      "nct_id": "NCT00241527",
      "title": "Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "NSAIDs",
        "Upper GI Symptoms"
      ],
      "interventions": [
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 556,
      "start_date": "2000-12",
      "completion_date": "2002-09",
      "has_results": false,
      "last_update_posted_date": "2011-01-24",
      "last_synced_at": "2026-09-21T08:42:10.259Z",
      "location_count": 32,
      "location_summary": "Tallassee, Alabama • Phoenix, Arizona • Garden Grove, California + 29 more",
      "locations": [
        {
          "city": "Tallassee",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00241527"
    }
  ]
}